Replay past webinars.


"Simplifying the management of T2D when a DPP4 inhibitor is needed"
November 6, 2018
Porto, Portugal

Part 1 TRAJENTA® Introduction Introduction

Watch the video:

Part 2 TRAJENTA® Patient case 1: Patient with normal kidney function Patient case 1: Patient with normal kidney function

Watch the video:

Part 3 TRAJENTA® Patient case 2: Potential for future kidney function decline Patient case 2: Potential for future kidney function decline

Watch the video:

Part 4 TRAJENTA® Patient case 3: Risk of non-compliance and potential for future kidney function decline Patient case 3: Risk of non-compliance and potential for future kidney function decline

Watch the video:

Part 5 TRAJENTA® Conclusion Conclusion

Watch the video:

TRAJENTA® Dr Per-Henrik Groop

Dr. Per-Henrik Groop

Helsinki, Finland

  • Nephrologist at University of Helsinki and Helsinki University Hospital, FInland

TRAJENTA® Dr Mike Cummings

Dr. Mike Cummings

Portsmouth, UK

  • Endocrinologist at Portsmouth Hospital NHS Trust Queen Alexandra Hospital, UK

TRAJENTA® Dr Mariana P. Monteiro

Dr. Mariana P. Monteiro

Porto, Portugal

  • Endocrinologist at University of Porto, Portugal


Treatment considerations for DPP-4 inhibitors in T2D:
a simple solution for a long-term outlook?

TRAJENTA® Treatment considerations for DPP-4 inhibitors in T2D: a simple solution for a long-term outlook?

Watch the video:

TRAJENTA® Dr Xavier Cos

Dr Xavier Cos

Barcelona, Spain

  • President of Primary Care Diabetes Europe (PCDE)
  • Director of Sant Marti de Provençals Clinical trials Unit
  • Associate Professor of Medicine, Universitat Autonoma de Barcelona, Spain

Dr. Cos is a general practitioner with a specific interest in primary prevention of diabetes, improving the quality of diabetes management and clinical trials of glucose-lowering therapies.

TRAJENTA® Dr Miguel A. Brito-Sanfiel

Dr Miguel A.
Brito-Sanfiel

Madrid, Spain

  • Endocrinologist at Hospital Universitario Puerta de Hierro
  • Assistant Professor in Endocrinology, Universidad Autónoma de Madrid, Spain

Dr. Miguel A. Brito-Sanfiel is an endocrinologist whose research focusses on the efficacy and safety of glucose-lowering therapies and the effect of hypercholesterolemia, obesity and diet on the development of diabetes.